Cargando…

Adverse drug reactions triggered by the common HLA-B*57:01 variant: a molecular docking study

BACKGROUND: Human leukocyte antigen (HLA) surface proteins are directly involved in idiosyncratic adverse drug reactions. Herein, we present a structure-based analysis of the common HLA-B*57:01 variant known to be responsible for several HLA-linked adverse effects such as the abacavir hypersensitivi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Den Driessche, George, Fourches, Denis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337232/ https://www.ncbi.nlm.nih.gov/pubmed/28303164 http://dx.doi.org/10.1186/s13321-017-0202-6

Ejemplares similares

Adverse drug reactions triggered by the common HLA-B*57:01 variant: virtual screening of DrugBank using 3D molecular docking
por: Van Den Driessche, George, et al.
Publicado: (2018)

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
por: Small, Catherine Butkus, et al.
Publicado: (2017)

Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides
por: Puig, Montserrat, et al.
Publicado: (2021)

Critical assessment of approaches for molecular docking to elucidate associations of HLA alleles with adverse drug reactions
por: Ramsbottom, Kerry A., et al.
Publicado: (2018)

HLA-B(*)58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand
por: Sukasem, Chonlaphat, et al.
Publicado: (2016)

Association of HLA-B*51:01, HLA-B*55:01, CYP2C9*3, and Phenytoin-Induced Cutaneous Adverse Drug Reactions in the South Indian Tamil Population
por: John, Shobana, et al.
Publicado: (2021)

HLA Association with Drug-Induced Adverse Reactions
por: Fan, Wen-Lang, et al.
Publicado: (2017)

HLA-B*57:01/Carbamazepine-10,11-Epoxide Association Triggers Upregulation of the NFκB and JAK/STAT Pathways
por: Haukamp, Funmilola Josephine, et al.
Publicado: (2023)

HLA‐associated adverse drug reactions ‐ scoping review
por: Jeiziner, Chiara, et al.
Publicado: (2021)

Peptide-Dependent Recognition of HLA-B*57:01 by KIR3DS1
por: O'Connor, Geraldine M., et al.
Publicado: (2015)

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies
por: Wu, Ran, et al.
Publicado: (2016)

HLA-B(*)13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?
por: Min, Fu-Li, et al.
Publicado: (2019)

Comparative Analysis of Real-Time Polymerase Chain Reaction Methods to Typing HLA-B*57:01 in HIV-1-Positive Patients
por: Falasca, Francesca, et al.
Publicado: (2016)

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA(®) observational database: a cohort study
por: Mounzer, Karam, et al.
Publicado: (2019)

A web resource for mining HLA associations with adverse drug reactions: HLA-ADR
por: Ghattaoraya, Gurpreet S., et al.
Publicado: (2016)

Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01
por: Cascella, R, et al.
Publicado: (2015)

Influence of Glycosylation Inhibition on the Binding of KIR3DL1 to HLA-B*57:01
por: Salzberger, Wilhelm, et al.
Publicado: (2015)

Unravelling the Proteomics of HLA-B*57:01(+) Antigen Presenting Cells during Abacavir Medication
por: Haukamp, Funmilola Josephine, et al.
Publicado: (2022)

HIV-1 Replication Fitness of HLA-B*57/58:01 CTL Escape Variants Is Restored by the Accumulation of Compensatory Mutations in Gag
por: Gijsbers, Esther F., et al.
Publicado: (2013)

Associations of HLA genetic variants with carbamazepine‐induced cutaneous adverse drug reactions: An updated meta‐analysis
por: Biswas, Mohitosh, et al.
Publicado: (2022)

Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01
por: Ogese, Monday O, et al.
Publicado: (2021)

HLA-A*24:02 as a common risk factor for antiepileptic drug–induced cutaneous adverse reactions
por: Shi, Yi-Wu, et al.
Publicado: (2017)

HLA-E*01:01 + HLA-E*01:01 genotype confers less susceptibility to COVID-19, while HLA-E*01:03 + HLA-E*01:03 genotype is associated with more severe disease
por: Hosseini, Ehteramolsadat, et al.
Publicado: (2023)

Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity
por: Metushi, Imir G., et al.
Publicado: (2015)

HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
por: Martínez Buitrago, Ernesto, et al.
Publicado: (2019)

Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa
por: Kolou, Malewe, et al.
Publicado: (2021)

HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients
por: Satapornpong, Patompong, et al.
Publicado: (2021)

CCM no. 80-01: no. 57
Publicado: (1980)

A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno
por: Senatore, C, et al.
Publicado: (2014)

HLA-A*11:01 is associated with levetiracetam-induced psychiatric adverse events
por: Yang, Tae-Won, et al.
Publicado: (2018)

HLA-B*58:01 allele is strongly associated with allopurinol-induced severe cutaneous adverse reactions in a Thai population
por: Jantararoungtong, Thawinee, et al.
Publicado: (2014)

Comparison of Methods for In-House Screening of HLA-B*57:01 to Prevent Abacavir Hypersensitivity in HIV-1 Care
por: De Spiegelaere, Ward, et al.
Publicado: (2015)

Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population
por: Koomdee, Napatrupron, et al.
Publicado: (2017)

HLA-A*11:01:01:01, HLA-C*12:02:02:01-HLA-B*52:01:02:02, Age and Sex Are Associated With Severity of Japanese COVID-19 With Respiratory Failure
por: Khor, Seik-Soon, et al.
Publicado: (2021)

Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors
por: Sooda, Anuradha, et al.
Publicado: (2022)

Improving turnaround times for HLA-B*27 and HLA-B*57:01 gene testing: a Barts Health NHS Trust quality improvement project
por: White, Emma, et al.
Publicado: (2021)

Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires
por: Scholz, Erika Margaret, et al.
Publicado: (2017)

Distinct antibody profiles in HLA-B(∗)57(+), HLA-B(∗)57(−) HIV controllers and chronic progressors
por: Klingler, Jéromine, et al.
Publicado: (2022)

Functional and structural characteristics of HLA-B*13:01-mediated specific T cells reaction in dapsone-induced drug hypersensitivity
por: Jiang, Haiqin, et al.
Publicado: (2022)

HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese
por: Nguyen, Dinh Van, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uki4bdq1qu08lcak9neucri52j